Covid Vaccine Race

Jason Gallagher, PharmD, adds context behind the FDA and CDC's decision to pause and review blood clotting events in 6 women given the company's COVID-19 vaccine.

In a press conference this morning, leadership of the FDA and CDC discussed why they made the decision on this vaccine and announced an ACIP meeting will be held tomorrow to review the data from the adverse events.

The federal agencies will advise states withhold administration of the Johnson & Johnson one-shot product while investigating risk of a rare blood clot disorder.

Our editor-in-chief writes on the role caregivers play in informing the public on the perks of a more vaccinated population.

Despite a growing number of cases, millions gather in India for Hindu festival.

With millions of people vaccinated for COVID-19, A new study, collecting data from CDC's v-safe program, discusses reactions following mRNA-based vaccines.

The company asked the Food and Drug Administration (FDA) to amend their Emergency Use Authorization (EUA) to include 12-15 year olds.

The newest research of rare adverse events among patients administered the vaccine highlights that venous or arterial thrombosis can develop in unexpected regions, including the brain or abdomen, 5-20 days after administration.

A new commentary from experts highlight the evolving understanding of antibody response in vaccinated transplant patients.

The United Kingdom’s Medicines and Healthcare products Regulatory Agency is making this recommendation for people in this age group after rare blot clots occurred after administration of the AstraZeneca vaccine.

The preclinical study showed that intranasal administration of OMV-Spike protected against the SARS-CoV-2 virus.

mRNA-1273 was seen to elicit antibodies for COVID-19 180 days following full dosage in a phase 1 trial and is still recommended for use by the authors.

The crossover will allow all trial participants to receive the vaccine while remaining blinded.

India recorded over 100,000 cases on Sunday, the countries highest daily total ever.

An expert stresses the need to consider individuals' worry over information—and even their history with systemic biases.

Vaccine access and new cases are both increasing. An expert discusses earning trust in at-risk communities.

The 2 revisions made to the EUA pertain to the number of doses allotted to the current vials containing the vaccine, and allow a new vial that has a maximum of 15 doses.

The companies are now seeking a Biologics License Application with the FDA, which would allow it to become more greatly available for adults in the US.

A manufacturing plant that was set to produce the Janssen (Johnson & Johnson) vaccine mixed up the ingredients of 2 vaccines.

The pivotal phase 3 data, based off 18 reported cases among placebo patients, includes the companies' intention to request authorization for adolescents aged 12-15 years old.

The country’s federal health agency decided upon this action based on the small number of vaccine-induced prothrombotic immune thrombocytopenia (VIPIT) incidents in Europe, which are being investigated.

Cases have increased by 16%, while 50 million have now been fully vaccinated. Federal leadership is asking Americans to hold on longer.

Intermediate-dose prophylactic anticoagulation did not improve mortality or venous or arterial thrombosis in patients with COVID-19 in the ICU compared with standard dosing, a new study found.

The Moderna and Pfizer-BioNTech vaccines are highly effective and transmission is unlikely.

England starts easing lockdown restrictions in hopes of removing most by early summer.

The companies announced they are expanding their study in children ages 6 months to 11 years old.

The president updated his goal during his press conference this afternoon.

Serum neutralizing antibodies to SARS-CoV-2 from infection or vaccination were found to recognize and act against new variants of the virus.

Overnight, the company restated it had a 76% efficacy against symptomatic disease and is looking to file an Emergency Use Authorization (EUA) with the Food and Drug Administration (FDA).

A statement hours after the company reported promising interim phase 3 data stated the Data Safety and Monitoring Board believes they included outdated data “which may have provided an incomplete view of the efficacy data.”